Ticker Launch
Sign inTry it free

SPAC · Deal announced · HSPOF

Horizon Space Acquisition I Corp.

Business combination with ArcheNova Biotech Corp.

Horizon Space Acquisition I Corp. (HSPOF) is a blank-check company (SPAC) that raised $60M in its initial public offering on Dec 22, 2022, listing on Nasdaq. It agreed to combine with ArcheNova Biotech Corp., announced on Oct 13, 2026, at a stated value of $2B. The deal has not closed yet. Network 1 led the IPO, with Financial. Robinson & Cole advised the SPAC and Sichenzia Ross Ference Carmel advised the underwriters on the IPO.

ArcheNova Biotech Corp. is a clinical-stage biopharmaceutical company developing drugs derived from MSC-derived extracellular vesicles and exosomes. It is advancing five product candidates across dermatology, orthopedics, ophthalmology, neurology and cardiology using its proprietary development and manufacturing platform.

Status
Deal announced
Ticker
HSPOF
IPO date
Dec 22, 2022
IPO size
$60M
IPO exchange
Nasdaq
Target
ArcheNova Biotech Corp.
Target sector
Biotech
Announced
Oct 13, 2026
Stated deal value
$2B
Combined company
ArcheNova Technology Co., Ltd
IPO underwriters
Network 1 and Financial
SPAC counsel (IPO)
Robinson & Cole and Maples and Calder
Underwriters' counsel (IPO)
Sichenzia Ross Ference Carmel

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other pending SPAC mergers